Table 3

Global incidence of indicated cancers, and estimates of total numbers eligible for treatment with selected TKIs

TKI and standard doseICD10 category and incidenceIndication of TKI, and percentage of relevant ICD10 groupEligibility in terms of pathology, and percentage of incident cases with this subtypeEligibility in terms of stage of disease, a percentage of incident cases at this stageTotal number newly eligible for indication, per yearTotal number newly eligible for TKI, per yearTotal API requirement per year, in tonnes, to meet incident demand
Imatinib 400 mg QDLeukaemia (C91–95), 351 965Chronic myeloid leukaemia, 12.3%Philadelphia chromosome positive, 87.5%NA, 100%37 88047 9997.0
Leukaemia (C91–95), 351 965Acute lymphoblastic leukaemia, 11.5%Philadelphia chromosome positive, 25%NA, 100%10 119
Erlotinib 150 mg QD for NSCLC, 100 mg QD for pancreatic cancerTrachea, bronchus and lung (C33–34), 1 824 701Non-small cell lung cancer, 85%Proportion of patients for whom EGFR status can be evaluated and are EGFR positive, 14.6%Advanced/metastatic, 83.5%189 082442 48619.6
Pancreatic cancer, 337 872Pancreatic cancer, 100%All, 100%Advanced/metastatic, 75%253 404
Sorafenib 400 mg BIDKidney cancer, 337 860Renal cell carcinoma, 85%All, 100%Advanced/metastatic, 71.5%205 334443 734129.6
Liver cancer, 782 451Hepatocellular carcinoma, 87.5%All, 100%Advanced/metastatic, 30%205 393
Thyroid cancer, 298 102Thyroid carcinoma, 95%Iodine-refractory, 66.6%Advanced/metastatic, 17.5%33 007
Lapatinib 1500 mg QDBreast cancer, 1 671 149Breast cancer, 100%HER-2 positive, 12.5%Advanced/metastatic, 33.5%69 97969 97938.3
  • Gastrointestinal stromal tumour, for which imatinib and sunitinib are indicated treatments in some cases, has not been included, due to its relative rarity, and the fact that it spans multiple ICD10 categories. References for figures used in this table can be found in online supplementary appendix 4.

  • API, active pharmaceutical ingredient; BID, two times a day; EGFR, epidermal growth factor receptor; ICD, International Classification of Diseases; NA, not applicable; NSCLC, non-small cell lung cancer; QD, daily; TKI, tyrosine kinase inhibitor.